Evidence map›Paper›PMID 42526440›Full record

ArticleCell reports. Medicine2026

An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer.

Yunru Gu, Chen Li, Yuhan Zhao, Tianrui Xu, Ye Zhu, Dandan Wang, Xiaoning Wang, Jiaxuan Chen, Jinbo Li, Xiaoxiang Guan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yunru GuDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Chen LiState Key Laboratory of Analytical Chemistry for Life Sciences, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China.
Yuhan ZhaoDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Tianrui XuDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Ye ZhuDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Dandan WangDepartment of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Xiaoning WangState Key Laboratory of Analytical Chemistry for Life Sciences, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China.
Jiaxuan ChenDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Jinbo LiState Key Laboratory of Analytical Chemistry for Life Sciences, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China. Electronic address: jinboli@nju.edu.cn.
Xiaoxiang GuanDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China. Electronic address: xguan@njmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) remains an aggressive malignancy lacking effective and safe treatments. Proteolysis-targeting chimeras (PROTACs) represent a promising modality for intractable diseases, but their application in TNBC is hindered by inefficient delivery. Here, we develop ASA, a TNBC-targeting antibody-PROTAC conjugate that links a TROP2-specific antibody to a BRD4-degrading PROTAC, with specificity conferred by TROP2-dependent endocytosis and hypoxia-triggered linker cleavage. ASA exhibits superior TNBC targeting and antitumor efficacy compared with its unconjugated PROTAC moiety. ASA monotherapy elicits stronger long-term immunological memory than the antibody-drug conjugate (ADC) sacituzumab govitecan, an effect that is further amplified by anti-PD-L1 combination. Mechanistically, ASA induces sustained BRD4 degradation, suppressing c-Myc and PD-L1 to inhibit tumor progression and drive long-lasting immunity. By disrupting DNA repair pathways, ASA synergizes with anti-PD-L1 to enhance tumor control and increase CD8

Indexed as

B7-H1 AntigenCell Cycle ProteinsImmunoconjugatesImmunotherapyProto-Oncogene Proteins c-mycTranscription FactorsTriple Negative Breast NeoplasmsAnimalsAntibodies, Monoclonal, HumanizedBromodomain Containing ProteinsCamptothecinCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMiceAntibodies, Monoclonal, HumanizedB7-H1 AntigenBRD4 protein, humanBromodomain Containing ProteinsCamptothecinCD274 protein, humanCell Cycle ProteinsImmunoconjugatesMYC protein, humanProteolysis Targeting ChimeraProto-Oncogene Proteins c-mycsacituzumab govitecanTranscription Factorsantibody-PROTAC conjugateCD8(+) T cellhypoxia responsiveimmunotherapylong-term immune memoryTNBCTROP2

Identifiers

PMID42526440
PMCPMC13522800

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.